allopurinol for the treatment of essential hypertension (ehtn) farahnak assadi, md emeritus...
TRANSCRIPT
![Page 1: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/1.jpg)
Allopurinol for the treatment of essential hypertension (EHTN)
Farahnak Assadi, MDEmeritus Professor of PediatricsChief Section of Nephrology
![Page 2: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/2.jpg)
Why Do Some People Develop EHTN?
Normal Weight/BP (60-80%)Obese/HTN (20-40%)
??
Obese/HTN: Overeat and exercise less BUT WHY?
![Page 3: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/3.jpg)
Why Do Some Kids Develop EHTN?
Normal Weight/BP(80-90%)Obese/HTN (10-20%)
??
Obese/HTN: Overeat and exercise less BUT WHY?
![Page 4: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/4.jpg)
Developmental Basis of Obesity HTN
Data indicating that obesity HTN has its origins during development and environmental chemicals exposures play a major role
A bad startthat lastsa lifetime!
![Page 5: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/5.jpg)
When Do Diseases Actually Start, and What Causes Diseases?
![Page 6: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/6.jpg)
Epigenetic(stable but plastic)
Genetic polymorphisms
(born with)
Inter-individual variability
Environmental factors
Susceptibility to Disease, Toxicants, Drugs, Altered behavior
(chemicals, diet, drugs, stress, behavior)
Both Genetics and Environment Factors Control Our Life
![Page 7: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/7.jpg)
Epigenetic Causes of Overeating and Lack of Exercise?
• Drug use (steroids, antidepressants, other meds?)
• Exposure to viruses (adenovirus 36)
• Environment– Stress (increased glucocorticoids)
– Nutrition (dietary salt)
– Lack of sleep
– Environmental chemicals
![Page 8: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/8.jpg)
Epidemiologic studies
• In Japanese the incidence of ETN approaches 50%• The mean sodium intake in Japanese is >400
mmol/day.• In Eskimo the average sodium intake is very low
<50 mmol/day and EHTN is virtually nonexistent.
©2007 RUSH University Medical Center
![Page 9: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/9.jpg)
Renal Handling of Sodium
• Excessive sodium intake alone is not sufficient to cause HTN, because the sodium retention and ECF volume expansion result in increased urinary sodium excretion that eventually normalize cardiac output and BP.
• Additional predisposing factors must exist that lead to the development of HTN in certain individual when the sodium intake is >60-70 mmol/day.
• Guyton AC. Hypertension 1987;10:1-6
©2007 RUSH University Medical Center
![Page 10: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/10.jpg)
©2007 RUSH University Medical Center
The role of kidney in SHR
Rettig R. J Human Hypertens 1993:7:177-180
![Page 11: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/11.jpg)
Role of kidney in Human EHTN
• In patients with ESRD due to EHTN, bilateral nephrectomy and a well-functioning allograft from a normotensive cadaver, cures EHTN
• Incidence of EHTN in recipients of cadaver kidneys correlates with the incidence of EHTN in the family of donors
• Curttis jj et al. N Engl J Med 1983;309:1009=1015• Guidi E, et al. Nephron 1985;41:14-21
©2007 RUSH University Medical Center
![Page 12: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/12.jpg)
Genes Causing EHTN
• Aldosterone synthesis gene (CYp11B2) mutations.
• Angiotensin II type 1 receptor gene (ATI) polymorphism.
• Endothelial nitric oxide synthesis gene (eNOS) mutations.
• G-protein β3 subunit gene (GNβ3) variant. • Caulfield M et al N Engl J Med 1994;330:1629-1633
• Benjafield AV et al. Hypertens.1998;32:1094-1097
• Siffert W, et al. Nat Genetics 1998;18:45-48
• Davies E, et al. Hypertens. 1999;33:703-707
![Page 13: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/13.jpg)
Impaired natriuresis: a prerequisite in EHTN• Increase ECF volume• Na/K ATPase inhibition• Increase ICF sodium concentration• Increase ICF calcium concentration• Vasoconstriction• Increase systemic vascular resistance• Development of EHTN
©2007 RUSH University Medical Center
Blaustein MP. Hypertension 1984;6:445-453
![Page 14: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/14.jpg)
Pathogenesis of EHTN
• There is a genetically predetermined impairment in the renal ability to excrete sodium or “impaired natriuretic capacity.”
• The prevalence of EHTN among offspring has been reported to be 46% if both parents are hypertensive, and 28% if one parent is hypertensive, and only 3% if neither parent is hypertensive.
©2007 RUSH University Medical Center
Ayman D. Arch Intern Med 1934;53:792-802
![Page 15: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/15.jpg)
Essential hypertension(EHTN)
• EHTN is a public Health problem worldwide and its burden on our health care system is becoming enormous.
• Many children with obesity are not aware that they have HTN.
• Over activity of renin-angiotensin system (RAS) is the main cause of primary HTN.
• RAS over activity can lead to myocardial hypertrophy, CVD and CKD and stoke.
©2007 RUSH University Medical Center
![Page 16: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/16.jpg)
![Page 17: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/17.jpg)
Douglas JG et al. Arch Intern Med 2003;163:525-541
![Page 18: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/18.jpg)
![Page 19: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/19.jpg)
![Page 20: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/20.jpg)
Reversal of LV Hypertrophy By Antihypertensive Treatment
Schmieder RE et al. JAMA. 2006
Ch
ang
e in
LV
mas
s in
dex
(%)
0
-5
-10
-15
-20
-25
Diuretics blockers
Calciumchannelblockers
ACE inhibitors
p<.01
p<.01
7%6%
9%
13%
![Page 21: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/21.jpg)
![Page 22: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/22.jpg)
Uric acid and EHTN
• EHTN is frequently associated with hyperuricemia in both adult and pediatric patients.
• More than 60% of children with EHTN have serum uric acid (UA) levels above 5.5 mg/dL.
• UA causes HTN through the activation of the RAS, down regulation of nitric oxide, and vascular endothelial dysfunction.
• Elevated UA level is a predictor of incident HTN and cardiovascular disease.
• Feig DI et al. JAMA 2008;300:924-932
![Page 23: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/23.jpg)
Hypothesis
• Treating EHTN with usual antihypertensive agents does not completely reduce cardiovascular risk related to uric acid (UA) levels.
• Lowering serum UA levels with allopurinol may provide greater benefit than simply treating HTN with the conventional therapy.
![Page 24: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/24.jpg)
Purpose of the study
• ACE inhibition in combination with allopurinol may reduce BP more effectively than ACE inhibitor alone in hyperuricemic children with newly diagnosed EHTN.
![Page 25: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/25.jpg)
Patients
• Forty- four children, aged 7-19 years, with newly diagnosed, never treated EHTN and serum UA levels > 5.5 mg/dL were studied.
• Patients were randomized in to two groups. Group 1 (n=20) received enalepril (0.3 mg/kg twice daily) for 8 weeks.
• Group 2 (n=24) received enalepril in combination with allopurinol (100 mg twice daily) for 8 weeks.
![Page 26: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/26.jpg)
Exclusion criteria
• Patients excluded if they had pre-HTN, stage 2 HTN, white-coat HTN or known renal, endocrine, gastrointestinal tract, hepatic or CVD.
• Also excluded were patients with a fasting blood sugar greater than 110 mg/dL,hemoglobin A1C greater that 6%, CVD, had treated with medications known to cause high BP or increase serum UA level.
![Page 27: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/27.jpg)
Characteristic Enalepril therapy (n=20)
Combined therapy
(n=24)
P value
Gender (N) Male (23)
Female (19)
Male (27)
Female (15)
NS
NS
Age, mean (year) 14.2 15.9 NS
BMI (%) 87 (86-89) 86 (85-90) NS
Systolic BP
(mmHg)
133 (129-136) 134 (128-137) NS
Diastolic BP (mmHg)
85 (82-86) 86 (80-97) NS
Serum UA
(mg/dL)
6.6 (5.9-7.4) 6.8 (6.1-7.6) NS
FEUA (%) 10.8 (8.1-12.3) 12.1 (8.7-12.4) NS
Patient population (pretreatment)
![Page 28: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/28.jpg)
Methods
• Random urine samples were collected for routine urinalysis and determinations of sodium and uric acid levels.
• Blood samples were drawn for electrolytes, creatinine and uric acid concentrations.
• Fractional excretion of uric acid were calculated using the standard formula.
![Page 29: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/29.jpg)
Parameter Mono therapy (GI)
(n=20)
Combined therapy (G II) (n=24)
P value
Change in systolic BP (mmHg)
-4.3 (-2.1 to -6.7) -8.2 (-7.2 to -9.8) 0.001
Change in diastolic BP
-2.4 (-1.1 to -2.2) -6.3 (-1.9 to -7.8) 0.006
Serum uric acid (mg/dL)
-5.1 (-5.8 to-6.7) -3.3 (-2.9 to-5.2) 0.002
FEUA
(%)
-3.3 (-3.4 to-4.1) -5.4 (-4.4 to-8.0) 0.004
Results
![Page 30: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/30.jpg)
Conclusions
• Allopurinol in combination with enalepril can reduce BP more effectively than enalepril alone in hyperuricemic children with newly diagnosed EHTN.
• Strategies to lower the risk of CVD in children with EHTN should include monitoring serum uric acid level treatment regimens that lower uric acid may be indicated to decrease the incidence of CVD by reducing serum uric acid level.
![Page 31: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/31.jpg)
Future Direction
• Increased dietary intake of fructose, which is a known cause of hyperuricemia, may be contributing to the current epidemic of obesity and HTN.
• Ongoing clinical trials will elucidate the role of uric acid in human HTN and will determine whether control of uuric acid may be a new way to prevent or treat EHTN.
![Page 32: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/32.jpg)
The End….but just the beginning
![Page 33: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/33.jpg)
©2007 RUSH University Medical Center
![Page 34: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/34.jpg)
Peripheral vascular disease
Morbidity
Disability
CKD
CADCHFLVHStroke
Hypertension
National High Blood Pressure Education Program Working Group, 2012
Hypertension (HTN): A Significant CV and Renal Disease Risk Factor
![Page 35: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/35.jpg)
Prevalence of CVD
10 20 30 40 50 60
High BP
CAD
CHF
Stroke
Other
50,000,000
12,200,000
4,600,000
4,400,000
2,800,000
Prevalence (millions)
BP=blood pressure, CAD=coronary artery disease, CHF=congestive heart failure
• Estimated Number of Persons With CVD in the US
(24%)
American Heart Association® . 2000 Heart and Stroke Statistical Update. 2009
![Page 36: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/36.jpg)
The Metabolic Syndrome*
*Diagnosis is established when 3 of these risk factors are present.†Abdominal obesity is more highly correlated with metabolic risk factors than is BMI. ‡Some men develop metabolic risk factors when circumference is only marginally increased.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.
<40 mg/dL<50 mg/dL
MenWomen
>102 cm (>40 in)>88 cm (>35 in)
MenWomen
110 mg/dLFasting glucose130/85 mm HgBlood pressure
HDL-C150 mg/dLTG
Abdominal obesity† (Waist circumference‡)
Defining LevelRisk Factor
![Page 37: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/37.jpg)
Dietary Approaches to Stop Hypertension (DASH)
• Diet high in fruits and vegetables and low-fat dairy products lowers blood pressure (11 mmHg SBP/ 5 mmHg DBP lower than traditional US diet), including more than a sodium-restricted diet
• Recommends 7-8 servings/day of grain/grain products, 4-5 vegetable, 4-5 fruit, 2-3 low- or non-fat dairy products, 2 or less meat, poultry, and fish
NEJM 1997; 366: 1117-24
![Page 38: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/38.jpg)
Lifestyle Modification
Modification Approximate SBP reduction(range)
Weight reduction 5–20 mmHg/10 kg weight loss
Adopt DASH eating plan
8–14 mmHg
Dietary sodium reduction 2–8 mmHg
Physical activity 4–9 mmHg
Moderation of alcohol consumption
2–4 mmHg
![Page 39: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/39.jpg)
Indications for Antihypertensive Drug Therapy in Children
with Stage 1 HTN
• Persistent HTN despite non-pharmacologic measures
• Symptomatic HTN• Secondary HTN• Hypertensive target-organ damage• Diabetes (types 1 and 2), CKD, obesity
![Page 40: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/40.jpg)
![Page 41: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/41.jpg)
![Page 42: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/42.jpg)
Evaluation: The Four Questions
• What is the cause of my hypertension?
– Primary hypertension most prevalent but secondary causes more common than in adults
– The younger the child and the more severe the hypertension; the more likely to be a secondary etiology
• What do we do about all this?
![Page 43: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/43.jpg)
Algorithm for Treatment of EHTN
Not at Goal Blood Pressure >95 percentile (in adolescents>125/75 mmHg even if less the 90 percentile)
Initial Drug Choices
Drug(s) for the compelling indications
Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB)
as needed.
With Compelling Indications
Lifestyle Modifications
Stage 2 Hypertension (>95th percentile + 5 mmHg) 2-drug combination for most
(usually thiazide-type diuretic and ACEI, or ARB, or BB, or CCB)
Stage 1 Hypertension
Between 95th and 99th percentile plus 5 Thiazide-type diuretics for most.
May consider ACEI, ARB, BB, CCB, or combination.
Without Compelling Indications
Not at Goal Blood Pressure
Optimize dosages or add additional drugs until goal blood pressure is achieved.
Consider consultation with hypertension specialist.
![Page 44: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/44.jpg)
Evaluation: The Four Questions
• Am I really hypertensive?Repetitive measurements/ABPM
• What risk factors for CVD do I have?Prmaturity, low birth weight, family history of
diabetes, hypercholesterolemia, CKD • What has HTN done to my body?
Look for end organ damage• CVD, CKD or stroke; • Evaluation of subtle subclinical changes
(microalbuminuria, non-dipper)
![Page 45: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/45.jpg)
Defining Pediatric HTN in children
Normal blood pressure BP <90th percentile
Pre-hypertension BP between 90th and 95th percentile, or if BP >125/75 mmHg even if < 90th percentile
Stage 1 hypertension BP between 95th and 99th percentile plus 5 mmHg
Stage 2 hypertension BP > 99th percentile + 5 mmHg
*Average SBP and DBP, on >3 occasions **Average SBP or DBP, on >3 occasions
The 4th Task Force Report on High BP in Children and Adolescents Pediatrics 2004; 114:555-574
![Page 46: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/46.jpg)
Causes of pediatric HTN
• Primary HTN is most prevalent• Secondary causes is more common than in
adults• The younger the child and the more severe
the HTN; the more likely to be a secondary etiology
©2007 RUSH University Medical Center
![Page 47: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/47.jpg)
Practical approach to diagnosis of HTN
Obtain UA, BMP, lipid profile, renal sonogram, ECHO
Normal Abnormal UA Abnormal sonogram Metabolic alkalosis
C3, ANA, ANCA Diuretic scan, VCUG DTPA scan, PRA/Aldo, MRA
Essential GN UPJ,VUR RVH, Hyperaldostronim
![Page 48: Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus Professor of Pediatrics Chief Section of Nephrology](https://reader035.vdocuments.mx/reader035/viewer/2022062520/56649ec05503460f94bcb63d/html5/thumbnails/48.jpg)
©2007 RUSH University Medical Center
Kidneys
Increased intraglomerular pressure
Increased protein leak
Glomerular growth and fibrosis
Increased sodium reabsorption
Decreased renal blood flow
Adapted from Opie and Gersh. Drugs for the Heart, 2001
Potential Pathogenic Propertiesof Angiotensin II